Returning for the seventh year, the 7th Antigen-Specific Immune Tolerance Summit (March 18 – 20, 2024 | Boston, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg, mRNA-LNP, biologic, peptide, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar.

This is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023, delve into your opportunity to create tolerizing, curative, strategies for autoimmunity, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts, industry super-giants, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature.

Expect to be involved in interactive discussions on:

• Tackle antigen-selection and deepen your understanding of the role of T-cells, B-cells and T-regs in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer.
• Build the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy, patient selection, and therapeutic durability with Takeda, University of Pittsburgh, Imcyse, and Anokion
• Assess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki
• Evaluate delivery technologies and novel approaches including CAR-Treg, mRNA-LNP, biologics, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma, Moderna, and Integrated Nanotherapeutics
• Harness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac, Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and more with GRO Bioscience, RheumaGen, NexImmune, and Parvus Therapeutics

Join 110+ autoimmune and immunologist scientists, corporate strategists, and large pharma scouts at this timely and comprehensive summit set to unite the immune tolerance field. From innovative, start-up biotechs to big pharma super giants, this is your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need.

Download the full agenda here to see our full speaker faculty, 3-day agenda and audience breakdown: https://ter.li/7teig8